Following discussions with children and young individuals with peanut allergies, experts have issued new guidelines for UK National Health Service (NHS) clinicians on the safe and fair implementation of Palforzia® peanut oral immunotherapy. These guidelines, detailed in the journal Clinical & Experimental Allergy, aim to provide comprehensive support to healthcare professionals. In 2022, the National Institute for Health and Care Excellence (NICE) in the UK endorsed the use of Palforzia®, which contains defatted peanut powder as its active component, for the desensitization of children and young people with peanut allergies within the NHS framework.
This latest consensus guidance is designed to assist healthcare providers in administering Palforzia® effectively, including the careful escalation of peanut dosage in patients. Dr Tom Marrs, PhD, from Guy’s and St Thomas’ NHS Foundation Trust and the corresponding author of the guidance, expressed enthusiasm about the advancements in treatment options: “It is significant that we can now provide an actual treatment for peanut allergy, moving beyond mere avoidance and patient education on reaction management. However, a current challenge within the NHS is ensuring that this treatment is accessible equitably to all eligible patients, irrespective of their geographic location or background. This guidance is crucial in outlining the necessities for NHS services to deliver this treatment extensively and champion patient advocacy, thereby establishing best practice models.”
More information: Tom Marrs et al, BSACI guidance for the implementation of Palforzia® peanut oral immunotherapy in the United Kingdom: A Delphi consensus study, Clinical & Experimental Allergy. DOI: 10.1111/cea.14491
Journal information: Clinical & Experimental Allergy Provided by Wiley
